Companion Animal Vaccines Market Report 2026

The companion animal vaccines market size has grown rapidly in recent years. It will grow from $4.55 billion in 2025 to $5.01 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to rising prevalence of infectious diseases in companion animals, growth in pet ownership globally, expansion of veterinary clinic networks, increased awareness of preventive pet healthcare, introduction of core vaccination programs for pets.

The companion animal vaccines market size is expected to see rapid growth in the next few years. It will grow to $7.41 billion by 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing demand for personalized pet healthcare solutions, growth in pet insurance coverage driving vaccination uptake, rising investment in advanced recombinant and mRNA vaccine platforms, expansion of emerging market veterinary infrastructure, growing focus on zoonotic disease prevention and global health security. Major trends in the forecast period include increasing pet humanization driving higher vaccination compliance and preventive healthcare adoption, rising awareness of zoonotic disease transmission boosting routine immunization in companion animals, expansion of veterinary healthcare infrastructure and clinic networks improving vaccine accessibility, growing use of combination and multivalent vaccines to reduce multiple injections and improve compliance, strengthening regulatory mandates and pet travel requirements enforcing vaccination standards.

The increasing spending on pet healthcare is expected to propel the growth of the companion animal vaccines market going forward. Pet healthcare spending refers to the total financial outlay by pet owners on veterinary services, preventive care, medications, and related health products for their companion animals. The increasing spending on pet healthcare due to the rising trend of pet humanization, where owners treat pets as family members, is a key contributing factor driving market expansion, as it encourages greater investment in preventive and routine veterinary care, including vaccinations, to support long-term animal well-being. The rising expenditure on pet healthcare is supporting and propelling the demand for companion animal vaccines, as pet owners increasingly seek preventive solutions to protect their animals from infectious and life-threatening diseases. For instance, in March 2024, according to the American Pet Products Association (APPA), a US-based trade association for the pet industry, veterinary care and product sales in the United States rose from $35.9 billion in 2022 to $38.3 billion in 2023, reflecting an increase of $2.4 billion. Therefore, increasing spending on pet healthcare is driving and supporting the growth of the companion animal vaccines market.

Leading companies operating in the companion animal vaccines market are focusing on developing innovative products such as injectable recombinant vaccines to enhance immunization effectiveness and improve administration flexibility. An injectable recombinant vaccine is a biologically engineered immunization that uses recombinant antigens to induce a targeted immune response in animals. For example, in November 2025, Zoetis Services LLC, a US-based animal health company, launched Vanguard Recombishield. It is a non-adjuvanted, recombinant injectable vaccine that incorporates the pertactin protein to enable more precise immune system targeting while reducing adverse reactions during administration. It also offers a more comfortable and versatile vaccination approach, supporting improved compliance and effective prevention of respiratory infections in dogs.

In June 2023, Mars Inc., a US-based manufacturing company, acquired Heska Corp. for an amount of $1.3 billion. This acquisition strengthens Mars Petcare's veterinary care capabilities and advances its commitment to improving pet health. Heska is now part of Mars Petcare's science and diagnostics division, including Antech Diagnostics. The integration enhances diagnostic services for veterinary professionals and pet owners, expanding access to advanced diagnostic technologies and accelerating research and development in veterinary healthcare. Heska Corp is a US-based veterinary services company specializing in developing, manufacturing, and commercializing advanced veterinary diagnostic and related vaccines for canine and feline health.

Major companies operating in the companion animal vaccines market are Boehringer Ingelheim International GmbH, Zoetis Inc., Ceva Santé Animale S. A., Virbac S. A., Phibro Animal Health Corporation, Neogen Corporation, Vetoquinol S. A., Norbrook Laboratories Limited, HIPRA S. A., Indian Immunologicals Limited, Vaxxinova International B. V., Bimeda Animal Health Limited, Laboratorios Calier S. A., Hester Biosciences Limited, ChoongAng Vaccine Laboratories Co. Ltd., Elanco Animal Health Incorporated, Bioveta a. s., CZ Veterinaria S. A., Intervet Inc. (Merck Animal Health), Brilliant Bio Pharma Private Limited, Durvet Inc., Kyoritsu Seiyaku Corporation.

North America was the largest region in the companion animal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the companion animal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the companion animal vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The companion animal vaccines market consists of sales of subunit vaccines, DNA vaccines, rabies vaccines, and distemper vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.